Amstat

Research use only, not for human use.

Tranexamic acid is an Antifibrinolytic Agent. The physiologic effect of tranexamic acid is by means of Decreased Fibrinolysis.

Tranexamic acid is an Antifibrinolytic Agent. The physiologic effect of tranexamic acid is by means of Decreased Fibrinolysis.

——

Animal Model:Traumatic brain injury (TBI) miceDosage:100 mg/kg Administration:Intravenous injection (i.v.)Result:Inhibited local plasmin formation and fibrinolysis.Impacts on the local immune response following TBI.Did not enhance reactivity of cervical lymph node (cLN) cells to central nervous system (CNS) antigens.Influences the cellular immune profile of peripheral lymph nodes.Reduced microglial and macrophage activation.Animal Model:Skin dryness induced wrinkles mice Dosage:750 mg/kg Administration:Oral Result:Resulted in the amelioration of transepidermal water loss (TEWL) and moisture retention.Suppressed the generation of wrinkles.Inhibited plasma concentrations of adrenocorticotropic hormone (ACTH), corticosterone, and IgE.

AMCA | TXA

Others

Other Targets

Plasminogen

Cardiovascular Disease

——

1197-18-8

157.21

C8H15NO2

>98% (HPLC)

Water: 31 mg/mL (197.18 mM)

O=C(C1CCC(CN)CC1)O

4-(aminomethyl)cyclohexane-1-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years